Lyell Immunopharma Inc (LYEL) Financials

$14.37

$0.05 (0.35%)

As on 04-Sep-2026 16:00EDT

Market cap

$352 Mln

Revenue (TTM)

$0 Mln

P/E Ratio

--

P/B Ratio

1.6

Div. Yield

0 %

Annual
Quarterly

Income Statement ($ Mln)	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Operating Revenue	0.03	0.04	0.06	0.13	84.68	10.65
Cost of Revenue	4.73	11.54	--	20.25	16.47	14.54
Gross Profit	-2.31	-11.50	0.06	0.13	84.68	10.65
Operating Expenses	189.75	192.27	358.82	247.14	271.74	225.43
Operating Profit (EBIT)	-192.06	-203.77	-358.76	-247.01	-187.06	-214.78
Other Income	--	--	--	--	--	-36.61
Profit before Tax	-248.48	-274.45	-342.99	-234.63	-183.12	-250.22
Provision for Tax	--	--	--	-10.53	-178.36	35.28
Profit after Tax (Net Income)	-248.48	-274.45	-342.99	-234.63	-183.12	-250.22
Minority Interest	--	--	--	--	--	--
Consolidated Profit	--	--	--	--	-183.12	-250.22

Liabilities ($ Mln)	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Shareholder's Funds	233.82	248.20	382.82	654.95	833.25	929.79
Minority Interest	--	--	--	--	--	--
Non-Current Liabilities	37.47	42.44	54.25	60.56	67.28	150.88
Current Liabilities	39.87	49.41	53.79	34.52	37.03	46.74
Total Liabilities	351.02	340.05	490.86	750.03	937.56	1,127.41

Assets ($ Mln)	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Non-Current Assets	97.61	79.11	111.27	195.34	286.27	501.12
Current Assets	213.54	260.94	379.59	554.69	651.30	626.29
Total Assets	351.02	340.05	490.86	750.03	937.56	1,127.41
Total Debt*	36.93	50.99	58.97	63.17	67.70	67.82
Net Current Assets	173.67	211.53	325.81	520.17	614.27	579.55

Cashflow ($ Mln)	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Cash From Operating Activities	--	-150.02	-162.39	-163.69	-169.56	-126.25
Cash Flow from Investing Activities	--	54.10	122.42	184.05	-11.54	-121.57
Cash from Financing Activities	--	50.41	1.33	1.74	10.64	401.24
Net Cash Inflow / Outflow	--	--	--	--	--	153.42

Financials Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Adjusted EPS ($)	-13.38	-16.06	-25.74	-18.54	-14.67	-20.62
Cash EPS ($)	--	-15.38	-24.26	-16.94	-13.23	-19.49
Adjusted Book Value ($)	--	14.52	28.73	51.76	66.78	76.61
Dividend per Share ($)	--	--	--	--	--	--
Cash Flow per Share ($)	--	-8.78	-12.19	-12.94	-13.59	-10.40
Free Cash Flow per Share ($)	--	-8.82	-12.22	-13.15	-15.53	-15.80

Profitability Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
ROCE (%)	--	-74.08	-59.14	-28.98	-19.29	-28.26
ROE (%)	-103.10	-86.98	-66.10	-31.53	-20.77	-30.36
ROA (%)	-64.26	-66.06	-55.28	-27.81	-17.74	-24.58
EBIT Margin (%)	-920,285.19	-762,355.56	-361,104.92	-180,486.15	-216.24	-2,349.47
Net Margin (%)	-920,285.19	-762,355.56	-562,285.25	-180,486.15	-216.24	963.94
Cash Profit Margin (%)	-0.10	--	--	--	--	--

Growth Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Revenue Growth (%)	-55.00	-0.41	-0.53	-1.00	6.95	0.37
EBIT Growth (%)	-21.12	-24.59	6.12	-28.13	26.82	-13.88
Net Profit Growth (%)	25.02	19.98	-46.18	-28.13	26.82	-22.37
EPS Growth (%)	44.95	0.38	-0.39	-0.26	0.29	-0.24
Book Value Growth (%)	-50.48	--	--	--	--	--

Valuation Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Price / Earnings	--	-1.92	-0.02	-0.10	-0.24	-0.38
Price / Book Value	1.56	2.12	0.02	0.04	0.05	0.10
Dividend Yield (%)	--	--	--	--	--	--
EV/EBITDA	0.25	-1.25	1.51	2.14	3.21	1.91
Close Price ($)	14.05	30.78	0.64	1.94	3.47	7.74
High Price ($)	45.00	45.00	3.26	3.97	8.74	19.84
Low Price ($)	8.87	0.39	0.58	1.32	2.74	6.90
Market Cap ($ Cr)	352.14	--	--	--	--	--

Solvency Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Debt to Equity	--	0.21	0.15	0.10	0.08	0.07
Short term debt to equity ratio	--	0.04	0.02	0.01	0.01	0.00
Current Ratio	5.36	5.28	7.06	16.07	17.59	13.40
Quick Ratio	5.36	--	--	--	--	--
Interest Coverage	--	--	--	--	--	-214.78

Operating Efficiency Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Debtors to sales (%)	--	--	--	--	--	--
Asset Turnover	0.00	0.00	0.00	0.00	0.08	0.01
Receivable days	--	--	--	--	--	--
Inventory Days	--	--	--	--	--	--
Payable days	--	130.71	--	78.77	79.01	158.35
Cash Conversion Cycle	--	--	--	--	--	--

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.